Cargando…

Validation of the Nanjing Criteria for Diagnosing Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstruction Syndrome

BACKGROUND AND AIMS: Hepatic sinusoidal obstruction syndrome (HSOS) is caused by toxic injury to sinusoidal endothelial cells in the liver. The intake of pyrrolizidine alkaloids (PAs) in some Chinese herbal remedies/plants remains the major etiology for HSOS in China. Recently, new diagnostic criter...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Wei, Liu, Lu, Zhang, Ming, Zhang, Feng, Peng, Chunyan, Zhang, Bin, Chen, Jun, Li, Lin, He, Jian, Xiao, Jiangqiang, Feng, Yanhong, Wang, Xunjiang, Xiong, Aizhen, Yang, Li, Zou, Xiaoping, Yu, Yuecheng, Zhuge, Yuzheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: XIA & HE Publishing Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237138/
https://www.ncbi.nlm.nih.gov/pubmed/34221920
http://dx.doi.org/10.14218/JCTH.2020.00124
_version_ 1783714671830761472
author Zhang, Wei
Liu, Lu
Zhang, Ming
Zhang, Feng
Peng, Chunyan
Zhang, Bin
Chen, Jun
Li, Lin
He, Jian
Xiao, Jiangqiang
Feng, Yanhong
Wang, Xunjiang
Xiong, Aizhen
Yang, Li
Zou, Xiaoping
Yu, Yuecheng
Zhuge, Yuzheng
author_facet Zhang, Wei
Liu, Lu
Zhang, Ming
Zhang, Feng
Peng, Chunyan
Zhang, Bin
Chen, Jun
Li, Lin
He, Jian
Xiao, Jiangqiang
Feng, Yanhong
Wang, Xunjiang
Xiong, Aizhen
Yang, Li
Zou, Xiaoping
Yu, Yuecheng
Zhuge, Yuzheng
author_sort Zhang, Wei
collection PubMed
description BACKGROUND AND AIMS: Hepatic sinusoidal obstruction syndrome (HSOS) is caused by toxic injury to sinusoidal endothelial cells in the liver. The intake of pyrrolizidine alkaloids (PAs) in some Chinese herbal remedies/plants remains the major etiology for HSOS in China. Recently, new diagnostic criteria for PA-induced HSOS (i.e. PA-HSOS) have been developed; however, the efficacy has not been clinically validated. This study aimed to assess the performance of the Nanjing criteria for PA-HSOS. METHODS: Data obtained from consecutive patients in multiple hospitals, which included 86 PA-HSOS patients and 327 patients with other liver diseases, were retrospectively analyzed. Then, the diagnostic performance of the Nanjing criteria and simplified Nanjing criteria were evaluated and validated. The study is registered in www.chictr.org.cn (ID: ChiCTR1900020784). RESULTS: The Nanjing criteria have a sensitivity and specificity of 95.35% and 100%, respectively, while the simplified Nanjing criteria have a sensitivity and specificity of 96.51% and 96.33%, respectively, for the diagnosis of PA-HSOS. Notably, a proportion of patients with Budd-Chiari syndrome (11/49) was misdiagnosed as PA-HSOS on the basis of the simplified Nanjing criteria, and this was mainly due to the overlapping features in the enhanced computed tomography/magnetic resonance imaging examinations. Furthermore, most of these patients (10/11) had occlusion or thrombosis of the hepatic vein, and communicating vessels in the liver were found in 8/11 patients, which were absent in PA-HSOS patients. CONCLUSIONS: The Nanjing criteria and simplified Nanjing criteria exhibit excellent performance in diagnosing PA-HSOS. Thus, both could be valuable diagnostic tools in clinical practice.
format Online
Article
Text
id pubmed-8237138
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher XIA & HE Publishing Inc.
record_format MEDLINE/PubMed
spelling pubmed-82371382021-07-01 Validation of the Nanjing Criteria for Diagnosing Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstruction Syndrome Zhang, Wei Liu, Lu Zhang, Ming Zhang, Feng Peng, Chunyan Zhang, Bin Chen, Jun Li, Lin He, Jian Xiao, Jiangqiang Feng, Yanhong Wang, Xunjiang Xiong, Aizhen Yang, Li Zou, Xiaoping Yu, Yuecheng Zhuge, Yuzheng J Clin Transl Hepatol Original Article BACKGROUND AND AIMS: Hepatic sinusoidal obstruction syndrome (HSOS) is caused by toxic injury to sinusoidal endothelial cells in the liver. The intake of pyrrolizidine alkaloids (PAs) in some Chinese herbal remedies/plants remains the major etiology for HSOS in China. Recently, new diagnostic criteria for PA-induced HSOS (i.e. PA-HSOS) have been developed; however, the efficacy has not been clinically validated. This study aimed to assess the performance of the Nanjing criteria for PA-HSOS. METHODS: Data obtained from consecutive patients in multiple hospitals, which included 86 PA-HSOS patients and 327 patients with other liver diseases, were retrospectively analyzed. Then, the diagnostic performance of the Nanjing criteria and simplified Nanjing criteria were evaluated and validated. The study is registered in www.chictr.org.cn (ID: ChiCTR1900020784). RESULTS: The Nanjing criteria have a sensitivity and specificity of 95.35% and 100%, respectively, while the simplified Nanjing criteria have a sensitivity and specificity of 96.51% and 96.33%, respectively, for the diagnosis of PA-HSOS. Notably, a proportion of patients with Budd-Chiari syndrome (11/49) was misdiagnosed as PA-HSOS on the basis of the simplified Nanjing criteria, and this was mainly due to the overlapping features in the enhanced computed tomography/magnetic resonance imaging examinations. Furthermore, most of these patients (10/11) had occlusion or thrombosis of the hepatic vein, and communicating vessels in the liver were found in 8/11 patients, which were absent in PA-HSOS patients. CONCLUSIONS: The Nanjing criteria and simplified Nanjing criteria exhibit excellent performance in diagnosing PA-HSOS. Thus, both could be valuable diagnostic tools in clinical practice. XIA & HE Publishing Inc. 2021-06-28 2021-03-31 /pmc/articles/PMC8237138/ /pubmed/34221920 http://dx.doi.org/10.14218/JCTH.2020.00124 Text en © 2021 Authors. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Zhang, Wei
Liu, Lu
Zhang, Ming
Zhang, Feng
Peng, Chunyan
Zhang, Bin
Chen, Jun
Li, Lin
He, Jian
Xiao, Jiangqiang
Feng, Yanhong
Wang, Xunjiang
Xiong, Aizhen
Yang, Li
Zou, Xiaoping
Yu, Yuecheng
Zhuge, Yuzheng
Validation of the Nanjing Criteria for Diagnosing Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstruction Syndrome
title Validation of the Nanjing Criteria for Diagnosing Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstruction Syndrome
title_full Validation of the Nanjing Criteria for Diagnosing Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstruction Syndrome
title_fullStr Validation of the Nanjing Criteria for Diagnosing Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstruction Syndrome
title_full_unstemmed Validation of the Nanjing Criteria for Diagnosing Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstruction Syndrome
title_short Validation of the Nanjing Criteria for Diagnosing Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstruction Syndrome
title_sort validation of the nanjing criteria for diagnosing pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237138/
https://www.ncbi.nlm.nih.gov/pubmed/34221920
http://dx.doi.org/10.14218/JCTH.2020.00124
work_keys_str_mv AT zhangwei validationofthenanjingcriteriafordiagnosingpyrrolizidinealkaloidsinducedhepaticsinusoidalobstructionsyndrome
AT liulu validationofthenanjingcriteriafordiagnosingpyrrolizidinealkaloidsinducedhepaticsinusoidalobstructionsyndrome
AT zhangming validationofthenanjingcriteriafordiagnosingpyrrolizidinealkaloidsinducedhepaticsinusoidalobstructionsyndrome
AT zhangfeng validationofthenanjingcriteriafordiagnosingpyrrolizidinealkaloidsinducedhepaticsinusoidalobstructionsyndrome
AT pengchunyan validationofthenanjingcriteriafordiagnosingpyrrolizidinealkaloidsinducedhepaticsinusoidalobstructionsyndrome
AT zhangbin validationofthenanjingcriteriafordiagnosingpyrrolizidinealkaloidsinducedhepaticsinusoidalobstructionsyndrome
AT chenjun validationofthenanjingcriteriafordiagnosingpyrrolizidinealkaloidsinducedhepaticsinusoidalobstructionsyndrome
AT lilin validationofthenanjingcriteriafordiagnosingpyrrolizidinealkaloidsinducedhepaticsinusoidalobstructionsyndrome
AT hejian validationofthenanjingcriteriafordiagnosingpyrrolizidinealkaloidsinducedhepaticsinusoidalobstructionsyndrome
AT xiaojiangqiang validationofthenanjingcriteriafordiagnosingpyrrolizidinealkaloidsinducedhepaticsinusoidalobstructionsyndrome
AT fengyanhong validationofthenanjingcriteriafordiagnosingpyrrolizidinealkaloidsinducedhepaticsinusoidalobstructionsyndrome
AT wangxunjiang validationofthenanjingcriteriafordiagnosingpyrrolizidinealkaloidsinducedhepaticsinusoidalobstructionsyndrome
AT xiongaizhen validationofthenanjingcriteriafordiagnosingpyrrolizidinealkaloidsinducedhepaticsinusoidalobstructionsyndrome
AT yangli validationofthenanjingcriteriafordiagnosingpyrrolizidinealkaloidsinducedhepaticsinusoidalobstructionsyndrome
AT zouxiaoping validationofthenanjingcriteriafordiagnosingpyrrolizidinealkaloidsinducedhepaticsinusoidalobstructionsyndrome
AT yuyuecheng validationofthenanjingcriteriafordiagnosingpyrrolizidinealkaloidsinducedhepaticsinusoidalobstructionsyndrome
AT zhugeyuzheng validationofthenanjingcriteriafordiagnosingpyrrolizidinealkaloidsinducedhepaticsinusoidalobstructionsyndrome